Determinants of paraoxonase activity in healthy adults

Molecular Nutrition and Food Research

Volumn 54, Issue 12, 2010, Pages 1842-1850

  Boesch Saadatmandi, Christine ^a   Rimbach, Gerald ^a   Schrader, Charlotte ^a   Kofler, Bettina M ^b   Armah, Christopher K ^b   Minihane, Anne M ^b,c  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF READING   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Age; ApoE genotype; Paraoxonase; Paraoxonase L55M; Paraoxonase Q192R

Indexed keywords

ALCOHOL DERIVATIVE; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CARBOXYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PON1 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BLOOD; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; ALCOHOLS; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL, HDL; FEMALE; GENOTYPE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 78649805039     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201000190     Document Type: Article

References (55)

1. Blatter, M. C., James, R. W., Messmer, S., Barja, F., Pometta, D., Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 1993, 211, 871-879.
2. Ng, C. J., Shih, D. M., Hama, S. Y., Villa, N. et al., The paraoxonase gene family and atherosclerosis. Free Radic. Biol. Med. 2005, 38, 153-163.
3. Mackness, B., Durrington, P., McElduff, P., Yarnell, J. et al., Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107, 2775-2779.
4. Soran, H., Younis, N. N., Charlton-Menys, V., Durrington, P. et al., Variation in paraoxonase-1 activity and atherosclerosis. Curr. Opin. Lipidol. 2009, 20, 265-274.
5. Aviram, M., Hardak, E., Vaya, J., Mahmood, S. et al., Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000, 101, 2510-2517.
6. Bhattacharyya, T., Nicholls, S. J., Topol, E. J., Zhang, R. et al., Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. J. Am. Med. Assoc. 2008, 299, 1265-1276.
7. Shih, D. M., Lusis, A. J., The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr. Opin. Lipidol. 2009, 20, 288-292.
8. Lawlor, D. A., Day, I. N., Gaunt, T. R., Hinks, L. J. et al., The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. Biomed. Chromatogr. Genet. 2004, 5, 17.
9. Mukamal, K. J., Pai, J. K., Jensen, M. K., Rimm, E. B., Paraoxonase 1 polymorphisms and risk of myocardial infarction in women and men. Circ. J. 2009, 73, 1302-1307.
10. Costa, L. G., Vitalone, A., Cole, T. B., Furlong, C. E., Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 2005, 69, 541-550.
11. Phuntuwate, W., Suthisisang, C., Koanantakul, B., Mackness, M. I., Mackness, B., Paraoxonase 1 status in the Thai population. J. Hum. Genet. 2005, 50, 293-300.
12. Roest, M., van Himbergen, T. M., Barendrecht, A. B., Peeters, P. H. et al., Genetic and environmental determinants of the PON-1 phenotype. Eur. J. Clin. Invest. 2007, 37, 187-196.
13. Cherki, M., Berrougui, H., Isabelle, M., Cloutier, M. et al., Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. Exp. Gerontol. 2007, 42, 815-824.
14. Saruhan, E., Olgun, A., Ozturk, K., Akman, S., Erbil, M. K., Age-related paraoxonase activity changes in Turkish population. Ann. NY Acad. Sci. 2007, 1100, 218-222.
15. Seres, I., Paragh, G., Deschene, E., Fulop Jr T., Khalil, A., Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp. Gerontol. 2004, 39, 59-66.
16. Vincent-Viry, M., Sass, C., Bastien, S., Aguillon, D. et al., PON1-192 phenotype and genotype assessments in 918 subjects of the Stanislas cohort study. Clin. Chem. Lab. Med. 2003, 41, 535-540.
17. Dietrich, M., Hu, Y., Block, G., Olano, E. et al., Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. Lipids 2005, 40, 329-334.
18. Talmud, P. J., Stephens, J. W., Hawe, E., Demissie, S. et al., The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann. Hum. Genet. 2005, 69, 613-622.
19. Hatters, D. M., Peters-Libeu, C. A., Weisgraber, K. H., Apolipoprotein E structure: insights into function. Trends Biochem. Sci. 2006, 31, 445-454.
20. Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F. et al., Association of apolipoprotein E genotypes with lipid levels and coronary risk. J. Am. Med. Assoc. 2007, 298, 1300-1311.
21. Minihane, A. M., Jofre-Monseny, L., Olano-Martin, E., Rimbach, G. H., Apolipoprotein E genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc. Nutr. Soc. 2007, 66, 183-197.
22. Song, Y., Stampfer, M. J., Liu, S., Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 2004, 141, 137-147.
23. Wilson, P. W., Schaefer, E. J., Larson, M. G., Ordovas, J. M., Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler. Thromb. Vasc. Biol. 1996, 16, 1250-1255.
24. Edelstein, C., Scanu, A. M., Precautionary measures for collecting blood destined for lipoprotein isolation. Methods Enzymol. 1986, 128, 151-155.
25. Lipid Research Clinics Program Manual of Laboratory Operations, DHEW Publications 1975.
26. Charlton-Menys, V., Liu, Y., Durrington, P. N., Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin. Chem. 2006, 52, 453-457.
27. Browne, R. W., Koury, S. T., Marion, S., Wilding, G. et al., Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay. Clin. Chem. 2007, 53, 310-317.
28. Aviram, M., Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol. Med. Today 1999, 5, 381-386.
29. van Himbergen, T. M., Roest, M., de Graaf, J., Jansen, E. H. et al., Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. Lipid Res. 2005, 46, 445-451.
30. Hixson, J. E., Vernier, D. T., Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 1990, 31, 545-548.
31. Minihane, A. M., Khan, S., Leigh-Firbank, E. C., Talmud, P. et al., ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1990-1997.
32. Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D. et al., High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79, 8-15.
33. Shih, D. M., Gu, L., Xia, Y. R., Navab, M. et al., Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394, 284-287.
34. Tward, A., Xia, Y. R., Wang, X. P., Shi, Y. S. et al., Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106, 484-490.
35. Can Demirdogen, B., Turkanoglu, A., Bek, S., Sanisoglu, Y. et al., Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clin. Biochem. 2008, 41, 1-9.
36. Wheeler, J. G., Keavney, B. D., Watkins, H., Collins, R., Danesh, J., Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004, 363, 689-695.
37. Lescai, F., Marchegiani, F., Franceschi, C., PON1 is a longevity gene: results of a meta-analysis. Ageing Res. Rev. 2009, 8, 277-284.
38. Gaidukov, L., Rosenblat, M., Aviram, M., Tawfik, D. S., The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J. Lipid Res. 2006, 47, 2492-2502.
39. Brophy, V. H., Jarvik, G. P., Richter, R. J., Rozek, L. S. et al., Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 2000, 10, 453-460.
40. Deakin, S., Leviev, I., Brulhart-Meynet, M. C., James, R. W., Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem. J. 2003, 372, 643-649.
41. Ferre, N., Camps, J., Fernandez-Ballart, J., Arija, V. et al., Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem. 2003, 49, 1491-1497.
42. van der Gaag, M. S., van Tol, A., Scheek, L. M., James, R. W. et al., Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999, 147, 405-410.
43. Sierksma, A., van der Gaag, M. S., van Tol, A., James, R. W., Hendriks, H. F., Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin. Exp. Res. 2002, 26, 1430-1435.
44. Rimm, E. B., Williams, P., Fosher, K., Criqui, M., Stampfer, M. J., Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. Br. Med. J. 1999, 319, 1523-1528.
45. Rao, M. N., Marmillot, P., Gong, M., Palmer, D. A. et al., Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003, 52, 1287-1294.
46. Mackness, B., Mackness, M. I., Arrol, S., Turkie, W. et al., Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998, 139, 341-349.
47. Leviev, I., Negro, F., James, R. W., Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2935-2939.
48. James, R. W., Deakin, S. P., The importance of high-density lipoproteins for paraoxonase-1 secretion, stability and activity. Free Radic. Biol. Med. 2004, 37, 1986-1994.
49. Minihane, A. M., Jofre-Monseny, L., Olano-Martin, E., Rimbach, G., ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc. Nutr. Soc. 2007, 66, 183-197.
50. Jofre-Monseny, L., Minihane, A. M., Rimbach, G., Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol. Nutr. Food Res. 2008, 52, 131-145.
51. Aviram, M., Dornfeld, L., Rosenblat, M., Volkova, N. et al., Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr. 2000, 71, 1062-1076.
52. Hayek, T., Fuhrman, B., Vaya, J., Rosenblat, M. et al., Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2744-2752.
53. de Roos, N. M., Schouten, E. G., Scheek, L. M., van Tol, A., Katan, M. B., Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women. Metabolism 2002, 51, 1534-1537.
54. Jarvik, G. P., Tsai, N. T., McKinstry, L. A., Wani, R. et al., Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1329-1333.
55. James, R. W., Leviev, I., Righetti, A., Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000, 101, 2252-2257.